Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.

Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.

Abstract: The present invention provides 3-{(2S,4S)-4-[4-(3-methyl -1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2 -ylcarbonyl}thiazolidine (compound I) useful as a dipeptidyl peptidase-IV inhibitor, which has superior properties of stability and hygroscopicity, and reproducible crystal structure, and a production method thereof.

Abstract: Provided is a positive electrode material for a safe, high capacity, long lifetime lithium ion secondary battery capable of large current charging and discharging. The positive electrode material contains between 5% by mass or more and 30% by mass or less of a carbon black composite formed by joining together fibrous carbon and carbon black wherein ash is 1.0% or less by mass in accordance with JIS K 1469 and the remainder includes olivine-type lithium iron phosphate, and volatile oxygen-containing functional groups which constitutes 1.0% or less by mass of the positive electrode material. The fibrous carbon is preferably a nanotube having a fiber diameter of 5 nm or more and 50 nm or less and a specific surface area between 50 m2/g or more and 400 m2/g or less.

Abstract: The invention provides a sulfonyl malonamide derivative, or a pharmacologically acceptable salt thereof or a solvate thereof, that has therapeutic and/or preventive effects(s) on various diseases due to its agonist action at AT2 receptor, and is useful as a pharmaceutical agent for the treatment and/or prevention of diseases involving the renin-angiotensin-aldosterone system (RAAS).

Abstract: Provided is a positive electrode material for a safe, high capacity, long lifetime lithium ion secondary battery capable of large current charging and discharging. The positive electrode material contains between 5% by mass or more and 30% by mass or less of a carbon black composite formed by joining together fibrous carbon and carbon black wherein ash is 1.0% or less by mass in accordance with JIS K 1469 and the remainder includes olivine-type lithium iron phosphate, and volatile oxygen-containing functional groups which constitutes 1.0% or less by mass of the positive electrode material. The fibrous carbon is preferably a nanotube having a fiber diameter of 5 nm or more and 50 nm or less and a specific surface area between 50 m2/g or more and 400 m2/g or less.

Abstract: The present invention provides a granulated acetylene black which can be easily and well dispersed when it is incorporated in at least one of a resin and a rubber, the process for producing it, and its composition. A granulated acetylene black has an average aspect ratio of at most 1.1, an average maximum particle size of from 0.2 mm to 1 mm and an average particle size of from 0.2 to 0.6 mm. The granulated acetylene black is produced, after stirring and granulating a mixture containing from 35 to 50 mass % of an acetylene black original powder having an iodine adsorption amount of from 80 to 100 mg/g and a DBP absorption amount of from 140 to 220 ml/100 g and from 50 to 65 mass % of water, and subjecting to selection treatment, classification treatment or both treatments.

Abstract: The present invention provides 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine (compound I) useful as a dipeptidyl peptidase-IV inhibitor, which has superior properties of stability and hygroscopicity, and reproducible crystal structure, and a production method thereof.

Abstract: The present invention provides 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine (compound I) useful as a dipeptidyl peptidase-IV inhibitor, which has superior properties of stability and hygroscopicity, and reproducible crystal structure, and a production method thereof.

Abstract: The present invention provides a granulated acetylene black which can be easily and well dispersed when it is incorporated in at least one of a resin and a rubber, the process for producing it, and its composition. A granulated acetylene black having an average aspect ratio of at most 1.1, an average maximum particle size of from 0.2 mm to 1 mm and an average particle size of from 0.2 to 0.6 mm. The granulated acetylene black is produced, after stirring and granulating a mixture containing from 35 to 50 mass % of an acetylene black original powder having an iodine adsorption amount of from 80 to 100 mg/g and a DBP absorption amount of from 140 to 220 ml/100 g and from 50 to 65 mass % of water, and subjecting to selection treatment, classification treatment or both treatments.

Abstract: The invention provides a sulfonyl malonamide derivative, or a pharmacologically acceptable salt thereof or a solvate thereof, that has therapeutic and/or preventive effect(s) on various diseases due to its agonist action at AT2 receptor, and is useful as a pharmaceutical agent for the treatment and/or prevention of diseases involving the renin-angiotensin-aldosterone system (RAAS).

Abstract: A thiazolidine derivative represented by the formula (I) wherein each symbol is as defined in the specification, and a pharmaceutically acceptable salt thereof exhibit a potent DPP-IV inhibitory activity, and can be provided as an agent for the prophylaxis or treatment of diabetes, an agent for the prophylaxis or treatment of obesity and the like.

Abstract: The present invention provides 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H -pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine (compound I) useful as a dipeptidyl peptidase-IV inhibitor, which has superior properties of stability and hygroscopicity, and reproducible crystal structure, and a production method thereof.

Abstract: A thiazolidine derivative represented by the formula (I) wherein each symbol is as defined in the specification, and a pharmaceutically acceptable salt thereof exhibit a potent DPP-IV inhibitory activity, and can be provided as an agent for the prophylaxis or treatment of diabetes, an agent for the prophylaxis or treatment of obesity and the like.

Abstract: The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the ?-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

Abstract: The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the ?-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

Abstract: The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the ?-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

Abstract: The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the ?-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

Abstract: A thiazolidine derivative represented by the formula (I) 1

Abstract: The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products.